JPH06504671A - Ｎｅｕを介して起こるトランスフォーメーションの抑制方法とそのための組成物 - Google Patents
Ｎｅｕを介して起こるトランスフォーメーションの抑制方法とそのための組成物Info
- Publication number
- JPH06504671A JPH06504671A JP4502955A JP50295592A JPH06504671A JP H06504671 A JPH06504671 A JP H06504671A JP 4502955 A JP4502955 A JP 4502955A JP 50295592 A JP50295592 A JP 50295592A JP H06504671 A JPH06504671 A JP H06504671A
- Authority
- JP
- Japan
- Prior art keywords
- eia
- gene
- neu
- cells
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims description 72
- 230000009466 transformation Effects 0.000 title claims description 29
- 239000000203 mixture Substances 0.000 title claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 180
- 108700020796 Oncogene Proteins 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 31
- 101000856426 Mus musculus Cullin-7 Proteins 0.000 claims description 28
- 206010027476 Metastases Diseases 0.000 claims description 26
- 108700020302 erbB-2 Genes Proteins 0.000 claims description 26
- 239000013598 vector Substances 0.000 claims description 26
- 230000009401 metastasis Effects 0.000 claims description 23
- 230000001404 mediated effect Effects 0.000 claims description 16
- 230000005740 tumor formation Effects 0.000 claims description 16
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 8
- 230000000381 tumorigenic effect Effects 0.000 claims description 8
- 230000001394 metastastic effect Effects 0.000 claims description 7
- 231100000588 tumorigenic Toxicity 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 230000010307 cell transformation Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 102000035160 transmembrane proteins Human genes 0.000 claims description 3
- 108091005703 transmembrane proteins Proteins 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims 3
- 101710187001 DNA terminal protein Proteins 0.000 claims 1
- 101710094581 Distal tail protein Proteins 0.000 claims 1
- 101710082836 Probable HNH endonuclease Proteins 0.000 claims 1
- 101710109927 Tail assembly protein GT Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 188
- 239000000047 product Substances 0.000 description 64
- 230000000694 effects Effects 0.000 description 52
- 102000004169 proteins and genes Human genes 0.000 description 39
- 206010028980 Neoplasm Diseases 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 26
- 238000012546 transfer Methods 0.000 description 24
- 230000001629 suppression Effects 0.000 description 21
- 238000013518 transcription Methods 0.000 description 21
- 230000035897 transcription Effects 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 241000701161 unidentified adenovirus Species 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 238000011580 nude mouse model Methods 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- 241000699660 Mus musculus Species 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 101150055766 cat gene Proteins 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 101100501691 Rattus norvegicus Erbb2 gene Proteins 0.000 description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 102000051957 human ERBB2 Human genes 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 208000005623 Carcinogenesis Diseases 0.000 description 7
- 241001135569 Human adenovirus 5 Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000036952 cancer formation Effects 0.000 description 7
- 231100000504 carcinogenesis Toxicity 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000001131 transforming effect Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 102000043276 Oncogene Human genes 0.000 description 6
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 102000040945 Transcription factor Human genes 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 102000048850 Neoplasm Genes Human genes 0.000 description 5
- 108700019961 Neoplasm Genes Proteins 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000009087 cell motility Effects 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- 238000012761 co-transfection Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 101100118548 Drosophila melanogaster Egfr gene Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 201000008026 nephroblastoma Diseases 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000037426 transcriptional repression Effects 0.000 description 3
- AVWQQPYHYQKEIZ-UHFFFAOYSA-K trisodium;2-dodecylbenzenesulfonate;3-dodecylbenzenesulfonate;4-dodecylbenzenesulfonate Chemical compound [Na+].[Na+].[Na+].CCCCCCCCCCCCC1=CC=C(S([O-])(=O)=O)C=C1.CCCCCCCCCCCCC1=CC=CC(S([O-])(=O)=O)=C1.CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O AVWQQPYHYQKEIZ-UHFFFAOYSA-K 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 206010056342 Pulmonary mass Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007773 growth pattern Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000713840 Avian erythroblastosis virus Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101150011777 E18 gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000109849 Leopardus jacobita Species 0.000 description 1
- 241000785747 Mavirus Species 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101150020201 RB gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940057324 biore Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940020452 neupro Drugs 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RONADMZTCCPLEF-UHFFFAOYSA-M tetrazolium violet Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C3=CC=CC=C3C=CC=2)=NN1C1=CC=CC=C1 RONADMZTCCPLEF-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000001912 transporting cell Anatomy 0.000 description 1
- ZSDSQXJSNMTJDA-UHFFFAOYSA-N trifluralin Chemical compound CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O ZSDSQXJSNMTJDA-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62146590A | 1990-12-04 | 1990-12-04 | |
| US621,465 | 1990-12-04 | ||
| PCT/US1991/009100 WO1992010573A1 (en) | 1990-12-04 | 1991-12-04 | Methods and compositions for the suppression of neu mediated transformation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001234289A Division JP3323491B2 (ja) | 1990-12-04 | 2001-08-01 | Ｎｅｕを介して起こる形質転換の抑制方法とそのための組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06504671A true JPH06504671A (ja) | 1994-06-02 |
Family
ID=24490270
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4502955A Withdrawn JPH06504671A (ja) | 1990-12-04 | 1991-12-04 | Ｎｅｕを介して起こるトランスフォーメーションの抑制方法とそのための組成物 |
| JP2001234289A Expired - Fee Related JP3323491B2 (ja) | 1990-12-04 | 2001-08-01 | Ｎｅｕを介して起こる形質転換の抑制方法とそのための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001234289A Expired - Fee Related JP3323491B2 (ja) | 1990-12-04 | 2001-08-01 | Ｎｅｕを介して起こる形質転換の抑制方法とそのための組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5651964A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0560932B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JPH06504671A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE142261T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU651650B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2096723C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69121903T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0560932T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2093248T3 (cg-RX-API-DMAC7.html) |
| GR (1) | GR3021805T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1992010573A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641484A (en) * | 1990-12-04 | 1997-06-24 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5643567A (en) * | 1990-12-04 | 1997-07-01 | Board Of Regents, The University Of Texas System | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen |
| US5516631A (en) * | 1992-10-13 | 1996-05-14 | La Jolla Cancer Research Foundation | Method of inhibiting replication of hyperproliferative cells |
| AU5962694A (en) * | 1992-12-31 | 1994-08-15 | Exemplar Corporation | Producing cells for transplantation to reduce host rejection and resulting cells |
| US5776743A (en) | 1994-09-06 | 1998-07-07 | La Jolla Cancer Research Foundation | Method of sensitizing tumor cells with adenovirus E1A |
| US6326356B1 (en) * | 1996-10-18 | 2001-12-04 | Board Of Regents, The University Of Texas System | Suppression of neu overexpression using a mini-E1A gene |
| US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5763415A (en) * | 1995-08-03 | 1998-06-09 | John Hopkins University School Of Medicine | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer |
| US6861506B1 (en) | 1996-01-11 | 2005-03-01 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| US6828431B1 (en) | 1999-04-09 | 2004-12-07 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US7241876B2 (en) | 1996-01-11 | 2007-07-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6656480B2 (en) | 1996-01-11 | 2003-12-02 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| CA2250222A1 (en) * | 1996-03-20 | 1997-09-25 | Mien-Chie Hung | Sensitization of her-2/neu overexpressing cancer cells to chemotherapy |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
| US6399743B1 (en) | 1999-05-14 | 2002-06-04 | Dept. Of Veterans Affairs | Isolation and characterization of a rat epidermal growth factor related protein |
| US9486429B2 (en) | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| BR0013814A (pt) | 1999-08-27 | 2002-04-23 | Genentech Inc | Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2 |
| US20040086903A1 (en) * | 2000-12-29 | 2004-05-06 | Jean-Jacques Lareyre | Epididymal lipocalin gene and uses thereof |
| US20020169126A1 (en) * | 2001-03-21 | 2002-11-14 | Mien-Chie Hung | Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene |
| US20050069918A1 (en) | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| US20100132058A1 (en) | 2004-07-23 | 2010-05-27 | Diatchenko Luda B | Methods and materials for determining pain sensitivity and predicting and treating related disorders |
| PT2247297T (pt) * | 2008-01-31 | 2019-04-24 | Univ Vanderbilt | Tratamento terapêutico para estados pulmonares |
| HUE045571T2 (hu) | 2008-01-31 | 2020-01-28 | Univ Vanderbilt | Koronáriás és artériás aneurizmás szubarachnoideális vérzés kezelésére szolgáló eljárások és készítmények |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4394448A (en) * | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| ES2067755T3 (es) * | 1989-06-22 | 1995-04-01 | Vestar Inc | Proceso de encapsulado. |
| ATE237694T1 (de) * | 1991-08-20 | 2003-05-15 | Us Gov Health & Human Serv | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
-
1991
- 1991-12-04 DK DK92902782.9T patent/DK0560932T3/da active
- 1991-12-04 AU AU91469/91A patent/AU651650B2/en not_active Ceased
- 1991-12-04 CA CA002096723A patent/CA2096723C/en not_active Expired - Fee Related
- 1991-12-04 JP JP4502955A patent/JPH06504671A/ja not_active Withdrawn
- 1991-12-04 WO PCT/US1991/009100 patent/WO1992010573A1/en not_active Ceased
- 1991-12-04 AT AT92902782T patent/ATE142261T1/de not_active IP Right Cessation
- 1991-12-04 ES ES92902782T patent/ES2093248T3/es not_active Expired - Lifetime
- 1991-12-04 EP EP92902782A patent/EP0560932B1/en not_active Expired - Lifetime
- 1991-12-04 US US08/070,410 patent/US5651964A/en not_active Expired - Fee Related
- 1991-12-04 DE DE69121903T patent/DE69121903T2/de not_active Expired - Fee Related
-
1996
- 1996-11-28 GR GR960403196T patent/GR3021805T3/el unknown
-
2001
- 2001-08-01 JP JP2001234289A patent/JP3323491B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69121903D1 (de) | 1996-10-10 |
| CA2096723C (en) | 2006-03-28 |
| EP0560932A1 (en) | 1993-09-22 |
| AU651650B2 (en) | 1994-07-28 |
| ATE142261T1 (de) | 1996-09-15 |
| DK0560932T3 (cg-RX-API-DMAC7.html) | 1997-02-17 |
| CA2096723A1 (en) | 1992-06-05 |
| JP2002114707A (ja) | 2002-04-16 |
| JP3323491B2 (ja) | 2002-09-09 |
| WO1992010573A1 (en) | 1992-06-25 |
| AU9146991A (en) | 1992-07-08 |
| ES2093248T3 (es) | 1996-12-16 |
| GR3021805T3 (en) | 1997-02-28 |
| US5651964A (en) | 1997-07-29 |
| DE69121903T2 (de) | 1997-04-10 |
| EP0560932B1 (en) | 1996-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06504671A (ja) | Ｎｅｕを介して起こるトランスフォーメーションの抑制方法とそのための組成物 | |
| Shirakata et al. | The× gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells | |
| Pozzatti et al. | The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells | |
| Nagata et al. | Activation of endogenous c-fos proto-oncogene expression by human T-cell leukemia virus type I-encoded p40tax protein in the human T-cell line, Jurkat | |
| US4419446A (en) | Recombinant DNA process utilizing a papilloma virus DNA as a vector | |
| Mansour et al. | Downstream sequences affect transcription initiation from the adenovirus major late promoter | |
| US5814315A (en) | Methods for the suppression of neu mediated phenotype in tumors | |
| US5641484A (en) | Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen | |
| Lanford et al. | Differential ability of a T-antigen transport-defective mutant of simian virus 40 to transform primary and established rodent cells | |
| Bedigian et al. | Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH mice | |
| JPH08507076A (ja) | 新形成の治療及び予防のための細胞障害ウイルス | |
| US12318418B2 (en) | Modified adenoviruses | |
| PL186151B1 (pl) | Zrekombinowane adenowirusy, kompozycje zawierające zrekombinowane adenowirusy, komórka gospodarza zainfekowana zrekombinowanym adenowirusem oraz sposób otrzymywania biologicznie aktywnego białka p53 typu dzikiego | |
| JP2001508290A (ja) | 新形成の治療及び予防のための細胞変性ウイルス | |
| JP2002508187A (ja) | Ｐ５３＋新生細胞の選択的殺死及び診断 | |
| US20020081279A1 (en) | Chicken embryo lethal orphan (CELO) virus | |
| Dini et al. | Mutations in the DNA-binding and transcriptional activation domains of v-Myb cooperate in transformation | |
| JPH09510346A (ja) | 哺乳動物細胞における新生物形質転換の制御に関連する遺伝子および遺伝学的因子 | |
| Kiyono et al. | The primary structure of major viral RNA in a rat cell line transfected with type 47 human papillomavirus DNA and the transforming activity of its cDNA and E6 gene | |
| Corallini et al. | Induction of malignant subcutaneous sarcomas in hamsters by a recombinant DNA containing BK virus early region and the activated human c-Harvey-ras oncogene | |
| Garcia et al. | Loss of heterozygosity for the short arm of chromosome 11 (11p15) in human milk epithelial cells immortalized by microinjection of SV40 DNA | |
| Doggett et al. | Structure, origin, and transforming activity of feline leukemia virus-myc recombinant provirus FTT | |
| Murphy et al. | Definition of a region required for transformation in E1a of adenovirus 12 | |
| Lamberti et al. | Differential requirement for adenovirus type 12 E1A gene products in oncogenic transformation | |
| EP1151094A1 (en) | Cervical cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20050801 |